Revolutionary Cell Therapies Funded with $100M! Game-Changing Breakthroughs Await!
Acepodia, a biotech company, has secured a significant investment of $100 million in a series D financing round. The funding will support Acepodia’s development of medicines for solid tumors and hematological cancers.
The round was led by Digital Mobile Venture, a notable investor who previously supported the company in a series C round. With this new investment, Acepodia has raised a total of $259 million so far.
The biotech plans to utilize the funds to advance two lead T-cell therapies: ACE1831, an off-the-shelf gamma delta T-cell therapy for patients with non-Hodgkin lymphoma, and ACE2016 for solid tumors expressing EGFR.
Recently, Acepodia announced the initiation of a phase 1 trial for ACE1831, with the first patient receiving a dose. The trial aims to determine the maximum tolerated dose and will include up to 42 patients in the United States. ACE2016 is still in the early stages of development.
Additionally, Acepodia will use the funds to enhance its antibody-cell conjugation technology platform, which applies click chemistry to live cells. This innovative platform is based on the groundbreaking work of Nobel Prize-winning scientist Carolyn Bertozzi, Ph.D.
Acepodia originated from the research laboratory of Dr
. Bertozzi at the University of California, Berkeley. CEO Sonny Hsiao, Ph.D., worked in her lab and helped establish the company. Another biotech, Lycia Therapeutics, also emerged from Dr. Bertozzi’s lab and focuses on next-generation protein degradation. Lycia Therapeutics raised $70 million in a series B financing round in September 2021.
